• Modifications of urato-oxalate exchange in patients with diabetes mellitus after maloinvasive treatment with ureterolytiaase induction

Modifications of urato-oxalate exchange in patients with diabetes mellitus after maloinvasive treatment with ureterolytiaase induction

HEALTH OF WOMAN. 2017.8(124):51–56; doi 10.15574/HW.2017.124.51  

Gurzhenko A. Yu.
National Medical Academy of Postgraduate Education P. L. Shupyk, Kiev

The objective: of the study was to study the status of urate-oxalate exchange in peple with ureterolithiasis and concomitant diabetes mellitus undergoing various methods of non-invasive surgical treatment of urinary stones.
Patients and methods. The study involved 164 patients and 12 healthy volunteers, of whom men accounted for 93 (56.7%), women – 71 (43.3%) persons. The age range of patients is 19–53 years, on average – 34.6±5.5 years. The average age of women is 30.1±2.9 years, and men are 37.6±3.1 years. Patients were divided into IV clinical groups: I – patients with ureterolithiasis and diabetes, which were performed by TUKL (n=34); II – patients with ureterolithiasis and diabetes, which were conducted by the EWHL (n=32); III – patients with ureterolithiasis without diabetes, which was performed by TUKL (n=41); IV – patients with ureterolithiasis without diabetes, which was performed by ESWL (n=57). The control group consisted of healthy volunteers with no signs of pathology (n=12). The studies were performed before and after disintegration of stones by the method of transurethral contact lithotripsy (TUKL) and ESWL. The diagnosis of SCH was verified using clinical, anamnestic, laboratory and instrumental research methods in accordance with the MOH protocols, before and after the disintegration of stones by the method of transurethral contact lithotripsy (TUCL) and ESWL.
Results.The analysis of the above-mentioned data found that in the presence of ureterolithiasis in people with diabetes, there were significant changes in daily pH indices in the form of monotony of the indicator curve, with a rather high shift towards acidification. Constant urine pH is an important marker for excretory renal function in the presence of urinary tract, diabetes, and diabetes. Strongly sour urine reflects the peculiarities of the flow of uratogenic urolithiasis in the conditions of the DN, indicating the absence of isolated violation by the GKO and outlines this state as a two-way.
Conclusion. Hypocytarturia was established in all cases of CKD, but in urine subjects with diabetes, excrement rates of citrate were as low as possible. In patients with diabetes mellitus and concomitant ureterolithiasis, there are significant disturbances in the metabolism of uric acid and oxalate, with the possibility of correction in case of rapid and complete recovery of urodynamics by noninvasive methods (TUKL).
Key words: ureterolithiasis, diabetes mellitus, urates, oxalates, minimally invasive methods of lithotripsy.

REFERENCES

1. Pasechnikov SP, Saidakova NO, Dmytryshyn SP. 2009. Dynamika efektyvnosti ta rivnia orhanizatsii spets. dopomohy patsiientam iz sechokamianoiu khvoroboiu v Ukraini. Zdorove muzhchіnу 1:164–171.

2. Habbig S, Beck B, Hope B. 2011. Nephrocalcinosis and urolitiasisin children B. Kidney Int. 80(12):1278–1291. https://doi.org/10.1038/ki.2011.336; PMid:21956187

3. Bova FS. 2010. Urolitaz i saharnyiy diabet. Osobennosti diagnostiki i lecheniya. Avtoref. dis. kand. med. nauk: 14.01.23 – Urologiya; 14.01.02 – Endokrinologiya. M:21.

4. Dziurak VS, Haiseniuk FZ. 1999. Patohenez, klasyfikatsiia ta likuvannia koralopodibnoho nefrolitiazu. Klin. khirurhiia 1:48–49.

5. Ngo TC, Assimos DG. 2007. Uric acid nephrolithiasis: recent progress and future directions. Rev. Urol. 9(1):17–27. PMid:17396168 PMCid:PMC1831527

6. Griffin MD, Bergstralhn EJ, Larson TS. 1995. Renal papillary necrosis – a sixteen-year clinical experience. J. Amer. Soc. Nephrol. 6:248–56. PMid:7579092

7. Pyitel YuA, Zolotarev II. 1995. Uratnyiy nefrolitaz. M, Meditsina:36.

8. Pereverzev AS, Rossihin VV, Ilyuhin YuA, Yaroslavskiy VL. 2004. Kamni pochek i mochetochnika. Harkov:240.

9. Tiktinskiy OL, Kalinina SM. 1996. Pielonefrityi. SPb, Piter:238.

10. Shtilvaser LM. 2004. Shliakhy pidvyshchennia efektyvnosti rannoi metafilaktyky z metoiu znyzhennia chastoty retsydyvnoho kameneutvorennia u khvorykh na sechokamianu khvorobu. Avtoref. dys. kand. med. nauk: 14.01.06 – Urolohiуa. K:22.

11. Avdoshin VP, Andryuhin MI, Israfilov MN i soavt. 2012. Lechenie i metafilaktika uratnogo i smeshannogo urolitiaza. Urologiya 3:7–10.

12. Kabak YuA. 2011. Profilaktyka retsydyvnoho kaltsii-oksalatnoho urolitiazu z vrakhuvanniam stanu metabolizmu shchavlevoi kysloty ta antyoksydantnoi systemy. Avtoref. dys. kand. med. nauk: 14.01.06 – Urolohiуa. K:20.

13. Asplin JR, Coe FL. 2007. Hyperoxaluria in Kidney Stone Formers Treated With Modern Bariatric Surgery. J.Urol. 1:565–569. https://doi.org/10.1016/j.juro.2006.09.033; PMid:17222634

14. Monico CG, Milliner DS. 2011. Genetic determinants of urolithiasis. Nat. Rev. Nephrol. 8(3):151–162. https://doi.org/10.1038/nrneph.2011.211; PMid:22183508 PMCid:PMC3901084

15. Dedov II, Kurbatov DG i soavt. 2009. Urologicheskie i andrologicheskie zabolevaniya pri saharnom diabete. Urologiya 4:74–79.

16. Dovlatyan AA, Kasabov AV. 2003. Ostryiy pielonefrit pri saharnom diabete. Urologiya 6:20–24.

17. Sobel JD. 1997. Pathogenesis of urinary tract infection. Role of host deferenses. Infect. Clin. North. Amer. 11:531–49. https://doi.org/10.1016/S0891-5520(05)70372-X

18. Ooi ST, Frazee LA, Gardner WG. 2004. Management of asymptomatic bacteriuria in patient with diabetes mellitus. Ann. Pharmacother. 38:490–493. https://doi.org/10.1345/aph.1D355; PMid:14970371

19. Stapleton A. 1997. Urinary tract infections in patient with diabetes. Amer. J. Med. 113(Suppl. 1A):72–75.